PARTNERS WITH
Temozolomide
Non-platinum based Alkylating Agents
MECHANISM OF ACTION
Temozolomide is a prodrug which is rapidly and nonenzymatically converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide]; this conversion is spontaneous, nonenzymatic, and occurs under physiologic conditions in all tissues to which it distributes . The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O6, N7 guanine positions which lead to DNA double strand breaks and apoptosis. Temozolomide is noncell cycle specific
MECHANISM OF KIDNEY INJURY
n/a
CLINICAL KIDNEY SYNDROME
BLE edema, urinary incontinence, increased urinary frequency
CARDIOVASCULAR ADVERSE EFFECTS
LYTE ABNORMALITIES
Hypercorticoidism, hepatotoxic, weight gain/edema
RISK FACTORS
n/a
MITIGATION STRATEGIES
n/a
SUGGESTIONS
Dose adjustment (details in notes section below), dose adjustment based on ANC and platelet counts
NOTES/COMMENTS
PHARMACOKINETICS
Molecular Weight
Volume of Distribution
Plasma Protein Binding
Metabolism
Bioavailability
Half-life elimination
Time to peak
Excretion
Urine (~38%; parent drug 6%;); feces <1%.
Dialyzable?
Unknown
REF:
PATHOLOGY SLIDES:
ENTRY UPDATES:
Kartik Kalra
United States
Sep 25, 2022